The Pharma Data

JULY 15, 2021

Antibody and T-cell immune responses strong and stable at eight months after immunization Demonstrated neutralizing antibody activity against the Delta variant (B.1.617.2) variants, as well as the original SARS-CoV-2 strain (WA1/2020). and other SARS-CoV-2 variants of concern , including the Alpha (B.1.1.7),

Immune Response 52

Immune Response Vaccine Clinical Trials FDA 52

The Pharma Data

DECEMBER 29, 2020

Experts believe brain-related effects may be tied to the body’s immune response to the virus and possibly to vascular problems or surges of inflammation caused by the disease. ” © 2020 HealthDay. Posted: December 2020. Colin Smith at Duke University Medical Center in Durham, N.C., told the Times.

Virus 52

Virus Hospitals Immune Response Doctors 52

The Pharma Data

NOVEMBER 3, 2020

Deucravacitinib works by inhibiting the tyrosine kinase 2 (TYK2) enzyme, which is linked to an immune response that causes skin inflammation. Bristol Myers Squibb (BMS) has reported positive results from a late-stage trial of its investigational drug, BMS-986165 (deucravacitinib), for treating moderate-to-severe plaque psoriasis.

Immune Response 52

Immune Response Drugs Trials Disease 52

The Pharma Data

DECEMBER 11, 2020

The university and CSL said while a phase 1 study evaluating candidate v451 showed it delivered a strong immune response and had a positive safety profile, vaccine trials will not progress to phase 2/3 trials given the possibility of interference with HIV tests.

Vaccine 52

Vaccine Immune Response Trials Government 52

DrugBank

JULY 18, 2024

Adjuvants are substances added to vaccines to enhance the immune response. They work by decreasing the solubility of the vaccine, which sustains the release of the drug and prolongs the immune response. Even after a vaccine is approved and distributed, the pharmaceutical industry's responsibility does not end.

Vaccine 79

Vaccine Immune Response Clinical Trials Disease 79

The Pharma Data

DECEMBER 12, 2020

Sanofi and GlaxoSmithKline (GSK) have decided to push back the phase 2b trial of their adjuvanted COVID-19 vaccine after finding it produced only a weak immune response in older patients, delaying the potential delivery of a vaccine that could contribute to the mass vaccination effort in the U.S.

Vaccine 52

Vaccine Immune Response Trials Research 52

The Pharma Data

DECEMBER 31, 2020

Monthly News Roundup – December 2020. The vaccine teaches the cells to make a piece of the spike protein, which triggers an immune response to help prevent illness if later exposed to the virus. Posted: December 2020. Professional. Moderna and Pfizer’s COVID-19 Vaccines Roll Out in Early Phase.

FDA Approval 52

FDA Approval Vaccine FDA Treatment 52

The Pharma Data

DECEMBER 20, 2020

The vaccine “could have significant advantages over first-generation vaccines, either on its own or in combination with other vaccines to broaden and strengthen the immune response for long- term protection,” Scancell said. Source link.

Clinical Trials 52

Clinical Trials Vaccine Pharma Companies Trials 52

Drug Target Review

JANUARY 15, 2024

The pathogenesis of COPD is based on the innate and adaptive inflammatory immune response to the inhalation of toxic particles and gases. 2020 October 1 [2024 January 5]; 27(4):523-31. Chronic obstructive pulmonary disease Chronic obstructive pulmonary disease (COPD) is the third leading cause of global deaths. Cell Stem Cell.

Immune Response 113

Immune Response Disease Science Therapies 113

The Pharma Data

DECEMBER 7, 2020

China’s Clover Biopharmaceuticals has announced its COVID-19 S Trimer vaccine candidate delivered a “strong immune response” in 150 adult and elderly phase 1 trial participants, with pre-publication results to be released soon.

Vaccine 52

Vaccine Immune Response Trials Research 52

The Pharma Data

NOVEMBER 18, 2020

19, 2020 /PRNewswire/ — OBI Pharma, Inc. “Based upon our anti-Globo H targeted approaches in cancers of high unmet needs, OBI Pharma is proud to have presentations on the progress of our trial presented at ESMO-Asia 2020 for our novel therapeutic cancer vaccine, OBI-833.” TAIPEI, Taiwan , Nov. About OBI Pharma.

Vaccine 52

Vaccine Small Molecule Immune Response Hospitals 52

The Pharma Data

DECEMBER 14, 2020

The company announced positive phase 1 trial results in November that demonstrated its candidate elicited immune responses and was well-tolerated. “We are hopeful that this trial will continue to demonstrate the impact of mRNA technology,” said CureVac CEO Franz-Werner Haas.

Vaccine 52

Vaccine Trials Immune Response RNA 52

The Pharma Data

DECEMBER 7, 2020

China’s Clover Biopharmaceuticals has announced its COVID-19 S Trimer vaccine candidate delivered a “strong immune response” in 150 adult and elderly phase 1 trial participants, with pre-publication results to be released soon.

Vaccine 52

Vaccine Immune Response Clinical Trials Trials 52

The Pharma Data

DECEMBER 7, 2020

7, 2020 — Scientists say they may be getting closer to creating a universal flu vaccine. In an early-stage clinical trial with 65 volunteers in the United States, an experimental vaccine triggered strong immune responses to a wide range of flu virus strains and subtypes. © 2020 HealthDay. Posted: December 2020.

Vaccine 52

Vaccine Immune Response Virus Clinical Trials 52

The Pharma Data

OCTOBER 27, 2020

27, 2020 — School-aged children seem to have the least severe disease for different infectious diseases, according to a study published online Oct. © 2020 HealthDay. . © 2020 HealthDay. Posted: October 2020. Professional. Infectious Disease Least Severe in School-Aged Children. TUESDAY, Oct. 15 in Scientific Data.

Disease 52

Disease Immune Response Vaccine Research 52

The Pharma Data

DECEMBER 31, 2020

31, 2020 — Blood vessel damage and inflammation in the brains of deceased COVID-19 patients suggest the damage is not caused by the virus, but the body’s immune response to it. The spots were surrounded by T cells — signs of an immune response. © 2020 HealthDay. Posted: December 2020.

Immune Response 52

Immune Response Virus Doctors Research 52

The Pharma Data

OCTOBER 27, 2020

27, 2020 /PRNewswire/ — Mirati Therapeutics, Inc. The offering is expected to close on or about October 30, 2020 , subject to customary closing conditions. SAN DIEGO , Oct. Nasdaq: MRTX) today announced the pricing of an underwritten public offering of 4,335,397 shares of its common stock at a price to the public of $202.00

Small Molecule 52

Small Molecule Immune Response Clinical Development Clinical Trials 52

Drug Target Review

OCTOBER 4, 2023

More recently, researchers have begun to look at conjugating immunomodulatory agents to antibodies to directly activate an immune response against the tumour. This approach – immune-stimulating antibody conjugates (ISACs) – uses a payload that stimulates the innate and adaptive immune responses, recruiting tumour-fighting T cells.

Small Molecule 126

Small Molecule Drugs Immune Response Targeted Protein Degradation 126

The Pharma Data

OCTOBER 21, 2020

22, 2020 (GLOBE NEWSWIRE) — Replimune Group, Inc. The offering is expected to close on October 26, 2020, subject to the satisfaction of customary closing conditions. BOSTON, Oct. Morgan Securities LLC, SVB Leerink LLC and Barclays Capital Inc. are acting as joint book-running managers for the offering.

Immune Response 40

Immune Response Clinical Trials Therapies Production 40

NIH Director's Blog: Drug Development

JUNE 30, 2020

But there is a catch: 99 percent of the study’s participants didn’t make enough neutralizing antibodies to mount an ideal immune response. That brings more reason for hope that the many vaccines now under study to elicit such neutralizing antibodies in sufficient numbers may afford us with much-needed immune protection.

Immune Response 52

Immune Response Virus Vaccine Research 52

The Pharma Data

JANUARY 25, 2021

In a surprise move, Merck announced that it is giving up on its two coronavirus vaccine candidates after seeing a subpar immune response and shifting its focus to a pair of investigational coronavirus treatments. MK-7110, previously known as CD24Fc, is a recombinant fusion protein that controls the body’s inflammatory response.

Vaccine 52

Vaccine Immune Response Trials Clinical Trials 52

Drug Target Review

OCTOBER 26, 2023

9 In addition, host immune responses further add to the complexity of developing cell-specific AAV capsids for clinical applications. It has been well established that exposure to wild-type AAV results in priming of the immune system against the virus. Nature 578 , 229-236 (2020). References Doudna JA. Ylä-Herttuala S.

Engineering 105

Engineering Virus Therapies Immune Response 105

The Pharma Data

NOVEMBER 16, 2020

Interim data from an early-stage trial indicated JNJ-78436735 delivered an immune response and was well-tolerated. The first part of the study, also enrolling 30,000 participants, is testing whether a single-dose regimen is effective. Jason Scott.

Vaccine 40

Vaccine Trials Immune Response Research 40

The Pharma Data

NOVEMBER 24, 2020

The FDA, which has not yet commented on the situation, could ask the company to collect more data due to the mistake, which could delay receiving Emergency Use Authorization (EUA).

Immune Response 40

Immune Response Vaccine Trials Regulations 40

The Pharma Data

NOVEMBER 18, 2020

While the vaccine generated immune responses in participants, it led to lower levels of antibodies than were seen in patients that recovered from COVID-19, the researchers said in The Lancet. James Miessler. Source link.

Vaccine 52

Vaccine Government Immune Response FDA 52

The Pharma Data

NOVEMBER 16, 2020

16, 2020 — Scientists are reporting early success with an experimental herpes vaccine that uses a genetically modified version of the virus. The gene edit prevents the virus from performing its normal evasive maneuver: hiding out in nervous system cells in order to elude the immune system. © 2020 HealthDay. MONDAY, Nov.

Vaccine 52

Vaccine Immune Response Virus Clinical Trials 52

The Pharma Data

DECEMBER 16, 2020

16, 2020 (GLOBE NEWSWIRE) — Novavax , Inc. Currently in Phase 3 clinical testing in the United Kingdom for the prevention of COVID-19, NVX-CoV2373 is a recombinant protein vaccine adjuvanted with Novavax’ proprietary Matrix-M to enhance the immune response. GAITHERSBURG, Md., About Novavax. Novavax, Inc.?(Nasdaq:

Vaccine 52

Vaccine Government Immune Response Clinical Trials 52

The Pharma Data

MARCH 13, 2022

People who gained immunity – either through vaccination or exposure – against the original strain of SARS-CoV-2, the virus that causes COVID-19, also are likely to have some protection against the pathogen’s omicron variant. The samples were stored after the researchers measured the T cell response. population.

Virus 52

Virus Immune Response Vaccine Research 52

The Pharma Data

DECEMBER 8, 2020

8, 2020 — AstraZeneca’s COVID-19 vaccine is safe and effective, new data from late-stage trials shows. ” Previous clinical trials of the vaccine had found that the vaccine triggers antibody and T-cell immune responses, and is safe in people aged 18 and older. © 2020 HealthDay. Posted: December 2020.

Vaccine 52

Vaccine Trials Immune Response RNA 52

Drug Target Review

FEBRUARY 28, 2024

Earlier in his career, Mr Ho was responsible for FP&A and operational analysis at CuraGen Corporation and worked as an Associate on the Healthcare Investment Banking team at Cowen, Inc. She previously served as the VP and AVP of Operations and Innovation since August 2020. Cells 9(40):800 (2020). Holtmeier W, Kabelitz D.

Therapies 105

Therapies Engineering Molecular Biology Science 105

Creative Biolabs

JULY 12, 2020

Professor Florian Klein, the paper’s corresponding author, explained, “our goal is to better understand the immune response to SARS-CoV-2 and to identify highly potent antibodies that can be used to prevent and treat COVID-19.” They are expected to enter clinical development later this year.

Immune Response 52

Immune Response Laboratories Clinical Trials Clinical Development 52

The Pharma Data

NOVEMBER 18, 2020

18, 2020 — Children should be included in clinical trials for a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine at the earliest stages, according to a letter from the president of the American Academy of Pediatrics (AAP), on behalf of more than 67,000 pediatricians and pediatric medical and surgical subspecialists.

Vaccine 52

Vaccine Trials Immune Response Virus 52

The Pharma Data

DECEMBER 18, 2020

18, 2020 — Allergic reactions to vaccines are generally rare and people with common allergies are not more likely to have a reaction to the Pfizer-BioNTech COVID-19 vaccine, according to guidance released by the American College of Allergy, Asthma & Immunology (ACAAI). . © 2020 HealthDay. Posted: December 2020.

Vaccine 52

Vaccine Immune Response Treatment Drugs 52

The Pharma Data

JUNE 25, 2021

CureVac began development of mRNA-based COVID-19 vaccine candidates in January 2020. Phase 1 and 2a clinical trials of CVnCoV began in June and September 2020, respectively. The quality of the immune response was comparable to recovered COVID-19 patients, closely mimicking the immune response after natural COVID-19 infection.

Vaccine 52

Vaccine Trials Immune Response Virus 52

The Pharma Data

FEBRUARY 22, 2021

New Phase 2 study assesses potential for refined antigen formulation to achieve optimal immune response, including in older adults. Sanofi and GSK’s adjuvanted recombinant protein-based COVID-19 vaccine candidate was selected in July 2020 by the U.S. In parallel, development work on new SARS-CoV-2 variants underway.

Vaccine 52

Vaccine Immune Response Trials Clinical Trials 52

The Pharma Data

DECEMBER 22, 2020

22, 2020 — In very rare cases, some people have had severe allergic reactions after receiving the new COVID-19 vaccines, leading the American College of Allergy , Asthma, and Immunology (ACAAI) to issue updated guidance for Americans with allergies. © 2020 HealthDay. Posted: December 2020. TUESDAY, Dec. Source link.

Vaccine 52

Vaccine Immune Response Treatment Disease 52

The Pharma Data

DECEMBER 3, 2020

4, 2020 08:00 UTC. Strong Th1 cell-mediated immune responses were also observed for the vaccine candidates with either adjuvant. A global Phase 2/3 efficacy study of the S-Trimer vaccine candidate in combination with GSK’s pandemic adjuvant system is expected to begin in December 2020. CHENGDU, China.–(

Vaccine 52

Vaccine Immune Response Virus RNA 52